



OFFICE of the DEPUTY PRIME MINISTER  
MINISTRY for HEALTH  
15, PALAZZO CASTELLANIA, MERCHANTS STREET, VALLETTA, MALTA

**DH Circular 72/2020**  
DH 955/2020

20<sup>th</sup> October 2020

**Attention All:** Consultants  
Medical Officers  
Pharmacists  
Pharmacy Technicians  
Nurses

**Cinacalcet 30mg Tablets, Everolimus 0.25mg and 0.75mg Tablets and Tiopronin 250mg Tablets**

As part of Government's initiative to continue increasing the access to medicines, it is being brought to your attention that Cinacalcet 30mg tablets, Everolimus 0.25mg and 0.75mg tablets, and Tiopronin 250mg tablets are now available on the Government Formulary List for in-patient and out-patient use.

Cinacalcet 30mg tablets can be prescribed by Consultant Nephrologists, Consultant Oncologists and Consultant Endocrinologists as per protocol 48 (Annex 1).

Everolimus 0.25mg and 0.75mg tablets can be prescribed by Consultant Nephrologists as per protocol 71 (Annex 2).

Tiopronin 250mg tablets can be prescribed by Consultant Nephrologists, Consultant Paediatric Nephrologists and Consultant Urologists as per protocol 193 (Annex 3).

For your attention please.

Dr. Denis Vella Baldacchino  
Chief Medical Officer

## **Cinacalcet 30mg Tablets**

### **Part A**

**Prescriber criteria:** Consultant Nephrologist

**Inpatient and Outpatient use:**

1. Chronic Kidney Disease

Treatment of refractory secondary hyperparathyroidism.

### **Part B**

**Prescriber criteria:** Consultant Oncologist  
Consultant Endocrinologist

**Inpatient and Outpatient use:**

1. Malignant Diseases

Hypercalcaemia not responding to bisphosphonate therapy.

**Duration of Approval**

2 years

## **Everolimus 0.25mg and 0.75mg Tablets**

**Prescriber Criteria:** Consultant Nephrologist

**Out-patient and In-patient use:**

1. Chronic Kidney Disease

- Prophylaxis of organ rejection in adult patients at low to moderate immunological risk receiving an allogeneic renal transplant.
  
- Prophylaxis of organ rejection in:
  - Calcineurin Inhibitor minimization or withdrawal
  - Malignancy
  - Severe viral infection
  
- Graft rejection while on classic immunosuppressant therapy

**Duration of Approval:**

2 years

## **Tiopronin 250mg Tablets**

**Prescriber Criteria:** Consultant Nephrologist  
Consultant Paediatric Nephrologist  
Consultant Urologist

**Inpatient and Outpatient use:**

1. Chronic Kidney Disease

Prevention and treatment of cystine kidney stone formation in patients with cystinuria.

**Duration of approval:**

2 years